Emergo Therapeutics has a total of 29 patents globally, out of which 7 have been granted. Of these 29 patents, more than 75% patents are active. The United States of America is where Emergo Therapeutics has filed the maximum number of patents, followed by Europe (EPO), Australia, Canada and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Emergo Therapeutics.
Emergo Therapeutics was founded in 2017. Emergo Therapeutics, is a medicine company, creates treatments to ease symptoms of flu and similar illnesses.
Do read about some of the most popular patents of Emergo Therapeutics which have been covered by us in this article and also you can find Emergo Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Emergo Therapeutics patent portfolio.
How many patents does Emergo Therapeutics have?
Emergo Therapeutics has a total of 29 patents globally. These patents belong to 3 unique patent families. Out of 29 patents, 22 patents are active.
How Many Patents did Emergo Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Emergo Therapeutics Applications Filed | Emergo Therapeutics Patents Granted |
| 2023 | 1 | – |
| 2022 | – | 2 |
| 2021 | – | 2 |
| 2020 | 1 | – |
| 2019 | 6 | 2 |
| 2018 | 1 | 1 |
| 2017 | 20 | – |
How many Emergo Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Emergo Therapeutics File in Different Countries?
Countries in which Emergo Therapeutics Filed Patents
| Country | Patent |
| United States Of America | 5 |
| Europe (EPO) | 2 |
| Australia | 2 |
| Canada | 2 |
| Japan | 2 |
| Philippines | 1 |
| South Africa | 1 |
| Saudi Arabia | 1 |
| India | 1 |
| Brazil | 1 |
| Indonesia | 1 |
| Russia | 1 |
| Israel | 1 |
| Singapore | 1 |
| China | 1 |
| South Korea | 1 |
| Malaysia | 1 |
| Hong Kong (S.A.R.) | 1 |
| Mexico | 1 |
Where are Research Centers of Emergo Therapeutics Patents Located?
What Percentage of Emergo Therapeutics US Patent Applications Were Granted?
Emergo Therapeutics (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2 have been granted leading to a grant rate of 100%.
Below are the key stats of Emergo Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Emergo Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Myers Bigel PA | 2 | 100% |
List of Emergo Therapeutics patents
| Emergo Therapeutics Patents | Title |
| US11478463B2 | Mast Cell Stabilizers For Treatment Of Chronic Inflammatory Conditions |
| US11072648B2 | Mast Cell Stabilizers For Treatment Of Fever |
| US10501527B2 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| US10494420B2 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| US10160796B2 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| EP3528809A4 | Mast Cell Stabilizers For Treatment Of Chronic Inflammatory Conditions |
| EP3509596A4 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| CN109952101A | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| AU2023204000A1 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| CA3040420A1 | Mast Cell Stabilizers For Treatment Of Chronic Inflammatory Conditions |
| CA3036230A1 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| MX389999B | Mast Cell Stabilizers For The Treatment Of Hypercytokinemia And Viral Infection |
| RU2760682C2 | Mast Cell Stabilizers For The Treatment Of Hypercytokinemia And Viral Infection |
| SA519401254A | Mast Cell Stabilizers For The Treatment Of Cytokine Hyperemia And Viral Infection |
| HK40011695A | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| ID201906535A | Mast Cell Stabilizers For The Treatment Of Hypercytokinemia And Virus Infections |
| IL265208A0 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| BR112019004496A2 | Mast Cell Stabilizers For The Treatment Of Hypercytokinemia And Viral Infection |
| PH12019500513A1 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| SG11201902056PA | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| ZA201901633A | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| MYPI2019000588A0 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| JP2019533018A5 | Mast Cell Stabilizers For The Treatment Of Chronic Inflammatory Conditions |
| JP2019529541A5 | Mast Cell Stabilizers For The Treatment Of Hypercytokinemia And Viral Infections |
| AU2017325010A1 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| WO2018075574A1 | Mast Cell Stabilizers For Treatment Of Chronic Inflammatory Conditions |
| WO2018048989A1 | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
| KR1020190073365A | Mast Cell Stabilizers For The Treatment Of Cytokine Hypersecretion And Viral Infections |
| IN201917010051A | Mast Cell Stabilizers For Treatment Of Hypercytokinemia And Viral Infection |
What are Emergo Therapeutics key innovation segments?
What Technologies are Covered by Emergo Therapeutics?
The chart below distributes patents filed by Emergo Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Emergo Therapeutics thinks it’s important to protect particular technology inventions.
R&D Focus: How has Emergo Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Emergo Therapeutics?